术前同时放化疗加手术治疗食管癌的研究进展

Preoperative concurrent chemoradiotherapy followed by surgery for esophageal cancer

食管癌是常见的恶性肿瘤，患者初诊时病变多为中晚期，预后很差。多年来，行同时放化疗治疗食管癌取得了一些令人鼓舞的结果。为了提高疗效，国外目前较多地研究术前同时放化疗加手术治疗食管癌，初步结果尚令人满意，5年生存率可达到30％～40％；术前同时放化疗与单纯手术及与单纯同时教化疗相比较都显示出较好的疗效。术前同时放化疗加手术治疗的不良反应明显增加，但患者可以耐受。术前同时放化疗加手术治疗食管癌是一种有前途的治疗措施，值得进一步探讨。

As a common malignant in the world, esophageal cancer＇ s survival rate is very poor because of its advanced stage when being diagnosed. Concurrent chemoradiotherapy for esophageal cancer has been studied for many years and appears promising results. Currently, the most promising strategy to improve the prognosis of advanced esophageal cancer is preoperative concurrent chemoradiotherapy followed by surgery. Some studies of this method have shown that 5-year-survival rate is 30%-40%, and others also show better treatment outcomes compared with surgery alone or definitive chemoradiotherapy. Furthermore this therapeutic modality is tolerated well by most patients considering the complications of treatment reported. Preoperative concurrent chemoradiotherapy followed by surgery for esophagus cancer is effective with substantial toxicities. Additional investigation is warranted.